Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest prevention of stroke Stories

2012-04-23 02:21:41

Bayer Inc. welcomes support for public reimbursement of new treatment TORONTO, April 23, 2012 /PRNewswire/ - Hundreds of thousands of Canadians living with atrial fibrillation (AF) are now one step closer to getting public reimbursement for a new stroke prevention therapy - news that was welcomed today by Bayer Inc. The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR), has positively recommended to Canada's provincial and...

2011-12-19 08:26:00

NEWBURY, England, December 19, 2011 /PRNewswire/ -- - First once-daily, fixed-dose preventative treatment for UK patients with non-valvular atrial fibrillation (an irregular heartbeat) at risk of the devastating consequences of stroke - Xarelto offers a convenient, cost-effective, single drug solution for the treatment of deep vein thrombosis (DVT) without the need for regular injections - Xarelto is now approved in the...

2011-08-11 12:43:37

In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be an attractive alternative to warfarin, the current standard for treatment of atrial fibrillation. The full intention-to-treat analysis, which includes patients who discontinued study drug, showed that rivaroxaban was noninferior to warfarin for...

2010-11-15 08:00:00

CHICAGO, Nov. 15, 2010 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that results from the pivotal Phase 3 double-blind ROCKET AF trial showed rivaroxaban given once daily was superior in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF) with comparable safety versus warfarin, the most commonly used medicine for the prevention of stroke in AF patients.(1) To view the multimedia...

2010-08-31 20:28:30

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data. The study leaders, principal investigator Dr. Stuart J. Connolly, chairman of the steering committee Dr. Salim...

2009-12-08 18:01:00

BRUSSELS, December 9 /PRNewswire/ -- - A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year - Affecting over six million people in Europe[1], AF, the most common, sustained abnormal heart rhythm, increases the risk of stroke five- fold[2] and is responsible for 15-20% of all strokes...